神經血管支架市場規模、佔有率和趨勢分析 | 全球市場 | 2026–2032 | 包括傳統神經血管支架、血流導向支架和其他一種類型

2025年全球神經血管支架市場規模為6.6億美元。預計該市場將以3.7%的複合年成長率成長，到2032年達到8.5億美元。

本報告涵蓋傳統神經血管支架、血流導向支架和囊內支架。報告定量分析了手術數量、銷售數量、平均售價、市場規模、成長率和企業市場占有率，包括截至 2022 年的歷史數據和截至 2032 年的預測數據。

受微創治療在複雜動脈瘤和血管疾病領域日益普及的推動，預計該市場在預測期內將保持穩定成長。血流導向支架佔據最大的市場佔有率，並在不斷擴大的臨床應用範圍內持續保持強勁成長。囊內支架的成長率最高，反映出醫師越來越傾向於微創治療以及新技術的廣泛應用。傳統神經血管支架是目前最成熟的細分市場，雖然成長速度較慢，但呈現較穩定的趨勢。

支架設計、自擴充性材料、生物相容性塗層和磁振造影相容結構等方面的技術進步，正在擴大可進行血管內治療的動脈瘤範圍。影像技術的改進提高了未破裂動脈瘤的檢出率，並擴大了符合治療條件的患者群體。老一代介入獸醫的抵抗情緒以及某些顱內動脈狹窄適應症臨床試驗的陰性結果是限制市場成長的主要結構性因素。

市場概覽

全球神經血管支架市場主要針對複雜顱內動脈瘤的血管內治療，例如寬頸動脈瘤、梭形動脈瘤和夾層動脈瘤等無法透過單純彈簧圈栓塞治療的動脈瘤。在該領域，三種器械類別各自發揮不同的臨床作用。傳統神經血管支架為寬頸動脈瘤的彈簧圈栓塞提供輔助支撐。血流導向支架主要用於大型和巨型動脈瘤，其作用是將血液從動脈瘤部位引流，促進腫瘤內血栓形成。囊內支架直接植入動脈瘤內，支撐瘤頸並將瘤囊與血液循環隔離，為某些特定形態的動脈瘤提供了微創的血流導向治療替代方案。

血流導引支架佔據最大的市場佔有率，並已確立了其作為大型和巨大寬頸動脈瘤一線治療方案的穩固臨床地位，這些動脈瘤不適合其他血管內治療。此細分市場受益於核准適應症的擴大以及醫生在血流導向支架置入方面經驗的累積。瘤內裝置是成長最快的細分市場，這主要得益於醫生對新技術的信心不斷增強，以及無需使用傳統支架輸送系統穿過動脈瘤頸部即可進行輸送和定位的裝置的吸引力。

技術進步是市場擴張的主要驅動力。自動擴張型支架設計、生物相容性塗層和磁振造影相容結構的改進，使神經血管支架植入術更加實用、安全，並能適應更廣泛的解剖觀察。隨著支架尺寸的縮小，它們可以植入更小的動脈和更遠端的位置，擴大了可治療的患者群體。這些進步的速度遠遠超過臨床試驗數據所能全面反映的速度，臨床應用往往領先正式的證據審查完成。

臨床證據在塑造這一市場中發揮了雙重作用。 SAMMPRIS試驗的陰性結果，以及後續研究對顱內支架置入治療狹窄的負面結果，促使FDA訂定監管規定，並在某些情況下改變了治療策略，不再採用支架輔助彈簧圈栓塞療法。另一方面，動脈瘤治療中血流導向裝置的長期證據基礎仍在不斷積累，越來越多的數據支持更廣泛地應用囊內裝置。儘管臨床證據的整體趨勢預計將推動市場擴張，但醫生的知識水平和對現有數據的解釋仍將繼續影響機構和區域層面的應用率。

市場促進因素

技術進步

神經血管領域的支架技術持續進步，在各方面都取得了顯著進展，使手術更加快捷簡便，同時降低了患者風險和醫生的抵觸情緒。自動擴張型支架的引入尤其重要，因為它能夠適應血管的解剖形態，避免了球囊擴張型支架植入過程中可能造成的組織損傷，從而能夠治療諸如寬頸動脈瘤、梭形動脈瘤和夾層動脈瘤等複雜疾病。生物相容性塗層和磁振造影相容材料的改進解決了血栓形成和術後影像學檢查等重要的臨床問題，擴大了支架的實際應用範圍，使其適用於更多患者。隨著支架尺寸的縮小和輸送性能的提升，在更小的動脈和更遠端的位置植入支架成為可能，從而拓寬了可治療病例的解剖學範圍。神經血管靜脈通路裝置的持續創新進一步推動了這一擴展，使支架能夠輸送到解剖結構複雜的部位。

醫學影像技術的進步

影像技術的進步提高了未破裂顱內動脈瘤的檢出率，使得更多患者被診斷為血管內治療的候選者。腦血管造影術、CT血管造影術和MRI均可用於檢測未破裂動脈瘤，隨著全球影像品質和普及程度的不斷提高，越來越多的患者在動脈瘤破裂前得到診斷。動脈瘤檢出率的提高直接轉化為治療需求的增加，從而推動了所有三種神經血管支架類別的銷售成長。此外，早期發現使得在動脈瘤增大或形態改變導致治療複雜化之前進行干預成為可能，這可能促使人們選擇支架治療而非保守治療。

市場限制

醫生的抵抗

介入性神經放射學領域的一些醫生對採用神經血管支架持謹慎態度。原因之一是這項技術在該領域相對較新，另一個原因是它需要專門的培訓和對操作的信心，而老一代介入放射科醫生在基礎培訓期間可能並未充分掌握這些技能。年輕醫師和應屆畢業生從一開始就接受過此類器械的培訓，通常熟悉支架置入術，也更傾向於將其應用於臨床實踐。隨著臨床數據在整體適應症方面的積累，以及支架技術在柔軟性、定位精度和易用性方面的不斷改進，醫生的抵抗情緒有望逐漸減弱。然而，在目前的預測期內，這很可能仍是某些醫療機構和地區（尤其是那些擁有在支架技術建立之前接受過培訓的經驗豐富的血管內放射科醫生的地區）推廣應用速度的一個重要阻礙因素。

不良臨床結果

2011 年的 SAMMPRIS 試驗表明，對於顱內動脈狹窄，積極的藥物治療比支架置入術更有效，這使得顱內動脈狹窄支架置放術的應用遭遇了重大挫折。基於這些結果，FDA 修訂了顱內支架置入術的適應症，開始逐步減少此適應症中的支架輔助彈簧圈置入術。 2015 年的 Vitesse 顱內支架研究專注於缺血性中風的治療，該研究支持了 SAMMPRIS 試驗的結果，並進一步鞏固了治療指南的轉變。 2021 年的一項研究為整體情況增添了一些細節，表明支架置入術在盡可能接近合格的事件發生時進行往往更安全。在血流導向治療領域，因安全問題而提前終止的「顱內動脈瘤血流導向治療試驗」的結果於2019年6月公佈。結果顯示，血流導向治療組有42%的患者未能達到主要終點，而標準治療組的比例為36%。目前仍需進行更多隨機對照試驗，以明確血流導向治療在不同類型動脈瘤和患者群體中的作用，而現有證據的不確定性也阻礙了其在某些臨床環境中的應用。

目錄

調查方法

• 第一步：專案啟動與團隊組建
• 步驟二：資料系統開發與二次調查實施
• 步驟三：準備面試設計問卷
• 第四步：進行初步調查
• 第五步：調查分析：基準估計
• 第六步：市場預測與分析
• 第七步：辨識策略機遇
• 步驟 8：最終確認和市場發布
• 步驟九：客戶回饋與市場監測

全球關稅的影響

神經血管支架市場

• 執行摘要
  • 全球神經血管支架市場概覽
  • 競爭分析
  • 涵蓋的治療
  • 目標市場
  • 目標區域
• 介紹
• 治療次數
  • 神經血管支架手術總數
  • 常規支架植入術
  • 血流導引支架手術
  • 囊內支架植入術
• 市場概覽
  • 按細分市場
  • 按地區
• 市場分析與預測
  • 神經血管支架市場
  • 傳統神經血管支架市場
  • 血流導向支架市場
  • 膀胱內支架市場
• 促進因素和抑制因素
  • 市場促進因素
  • 市場限制因素
• 競爭性市佔率分析

附錄

The global neurovascular stent market was valued at $660 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 3.7%, reaching $850 million by 2032.

This report covers traditional neurovascular stents, flow diversion stents, and intrasaccular stents. The report quantifies procedure numbers, unit sales, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.

The market is expected to demonstrate steady growth over the forecast period, driven by increasing adoption of minimally invasive treatments for complex aneurysms and vascular conditions. Flow diversion stents represent the largest portion of the market and continue to show solid growth supported by expanding clinical indications. Intrasaccular stents are growing at the fastest rate, reflecting rising physician preference for less invasive treatment options and broader adoption of newer technologies. Traditional neurovascular stents are the most mature segment, growing at a slower and more stable pace.

Technological advances in stent design, self-expanding materials, biocompatible coatings, and MRI-compatible construction are expanding the range of aneurysms that can be treated endovascularly. Improved imaging technologies are increasing the detection of unruptured aneurysms and expanding the treated patient population. Physician resistance among older-generation interventionalists and negative clinical trial results in specific intracranial stenosis indications are the primary structural constraints on market growth.

Market Overview

The global neurovascular stent market addresses the endovascular treatment of complex intracranial aneurysms, including wide-necked, fusiform, and dissecting presentations that are not amenable to simple coil occlusion. Three device categories serve distinct clinical roles within this space. Traditional neurovascular stents provide scaffolding to assist in the coiling of wide-necked aneurysms. Flow diversion stents redirect blood away from the aneurysm to promote thrombosis within the sac, primarily for large and giant aneurysms. Intrasaccular stents are deployed directly within the aneurysm to scaffold the neck and exclude the sac from circulation, offering a less invasive alternative to flow diversion for certain aneurysm morphologies.

Flow diversion stents represent the largest market segment, having established a strong clinical position as the preferred treatment for large and giant wide-necked aneurysms that are poorly suited to other endovascular approaches. The segment benefits from expanding approved indications and growing physician experience with flow diverter implantation. Intrasaccular devices are the fastest-growing segment, driven by increasing physician comfort with newer technology and the appeal of a device that can be delivered and positioned without the need to traverse the aneurysm neck with a conventional stent delivery system.

Technology advancement is the primary engine of market expansion. Self-expanding stent designs, improved biocompatible coatings, and MRI-compatible construction have made neurovascular stenting more practical, safer, and applicable to a wider range of anatomical presentations. As stents become smaller, they can be implanted in smaller arteries and more distal locations, expanding the treatable patient population. These advances are occurring more rapidly than can be fully characterized by clinical trial data, meaning real-world adoption frequently precedes the completion of formal evidence reviews.

Clinical evidence has played a mixed role in shaping this market. Negative results for intracranial stenting in the stenosis indication, established by the SAMMPRIS trial and confirmed by subsequent studies, led to FDA-imposed restrictions and a shift in practice away from stent-assisted coiling in certain settings. At the same time, the long-term evidence base for flow diversion in aneurysm treatment continues to build, and intrasaccular devices are accumulating data that supports broader adoption. The overall trajectory of clinical evidence is expected to support market expansion, though physician familiarity and interpretation of available data will continue to influence adoption speed across centers and geographies.

Market Drivers

Technological Advancement

Stent technology in the neurovascular space continues to improve across multiple dimensions, making procedures faster and easier while reducing patient risk and physician resistance. The introduction of self-expanding stent designs has been particularly significant, allowing stents to conform to vessel anatomy without the trauma associated with balloon-expandable deployment and enabling treatment of complex presentations including wide-necked, fusiform, and dissecting aneurysms. Improved biocompatible coatings and MRI-compatible materials have also addressed critical clinical concerns around thrombogenicity and post-implant imaging, expanding the practical usability of stents across patient populations. As stents become smaller and more deliverable, they can be implanted in smaller arteries and at more distal locations, broadening the anatomical scope of treatable cases. Continued innovation in neurovascular access devices is further supporting this expansion by enabling better stent delivery to difficult anatomy.

Improved Imaging Technologies

Advances in imaging technologies are increasing the detection rate of unruptured intracranial aneurysms, expanding the number of patients identified as candidates for endovascular treatment. Cerebral angiography, CT angiography, and MRI can all be used to detect unruptured aneurysms, and as imaging quality and availability continue to improve globally, more patients are being diagnosed before aneurysm rupture. An increase in the number of aneurysms detected translates directly into an increase in the number treated, which drives unit sales across all three neurovascular stent categories. Earlier detection also supports intervention before aneurysm enlargement or morphological changes complicate treatment, which can favor the use of stent-based approaches over more conservative management.

Market Limiters

Physician Resistance

Some physicians in the interventional neuroradiology community have displayed resistance to adopting neurovascular stents, partly because the technology is relatively new to the specialty and partly because it requires specialized training and procedural confidence that older-generation interventionalists may not have developed during their core training. Younger physicians and recent graduates who were trained with these devices from the outset are generally more comfortable with stenting and more likely to incorporate it into their practice. As more clinical data becomes available across indications and as stent technology continues to improve in terms of flexibility, positioning, and ease of deployment, physician resistance is expected to diminish progressively. However, during the current forecast period it remains a meaningful constraint on adoption speed in certain institutions and geographies where experienced endovascular practitioners trained before stent-based techniques were established.

Negative Clinical Results

Stent application for intracranial stenosis suffered a significant setback following the 2011 SAMMPRIS trial, which found that aggressive medical management was superior in efficacy to stenting for intracranial arterial stenosis. As a result of this trial, the FDA altered the criteria for intracranial stenting and a shift away from stent-assisted coiling in this indication began. The 2015 Vitesse Intracranial Stent Study for Ischemic Stroke Therapy confirmed the SAMMPRIS findings, reinforcing the practice change. A 2021 study indicated that stenting tended to be safer when performed closest to the qualifying event, providing some nuance to the overall picture. In the flow diversion segment, results from the Flow Diversion in Intracranial Aneurysm Treatment trials were published in June 2019 after the trial was cut short due to safety concerns, with 42% of patients allocated to flow diversion failing to reach the primary outcome compared to 36% in the standard treatment group. Further randomized trials are needed to clarify the role of flow diversion across aneurysm subtypes and patient populations, and uncertainty in the evidence base continues to moderate adoption in some clinical settings.

Market Coverage and Data Scope

• Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
• Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
• Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
• Data sources: Primary interviews with neurovascular device industry leaders and interventional neuroradiologists, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
• Care settings: Hospitals and neurovascular intervention centers.

Markets Covered and Segmentation

• The neurovascular stent market is analyzed across three device type categories, each assessed by procedure volume, unit volume, ASP, and market value with historical and forecast data:
• Traditional Neurovascular Stents
• Flow Diversion Stents
• Intrasaccular Stents

Competitive Analysis

Terumo held the leading position in the neurovascular stent market in 2025. The company offers the LVIS and LVIS Jr (Low-Profile Visualized Intraluminal Support) devices, which are designed to provide scaffold support for the coiling of wide-necked intracranial aneurysms. The low-profile design of the LVIS family allows delivery through smaller microcatheters and enables visualization of the stent during and after deployment, supporting precise placement in complex anatomy. Terumo's leadership in the stent segment is complemented by its broader commercial presence across the neurovascular device space.

Medtronic held the second-leading position in the global neurovascular stent market in 2025. The company competes through the Pipeline Flex, its current-generation flow diverting stent, as well as earlier Pipeline platform products. The Pipeline device redirects blood flow away from the aneurysm to promote thrombosis within the sac and is used primarily for large and giant wide-necked aneurysms. Medtronic's position in the flow diversion segment, which represents the largest share of market value within the neurovascular stent market, is a key driver of its overall competitive standing in this space.

Stryker was the third-leading competitor in the neurovascular stent market in 2025. The company competes through the Neuroform EZ stent system, a self-expanding open-cell stent designed for use as a scaffold to assist in the coiling of wide-necked intracranial aneurysms. The Neuroform EZ's delivery and positioning characteristics provide physicians with a tool for aneurysm stabilization during coil embolization in cases where the aneurysm neck geometry prevents reliable coil retention without stent support. Stryker's established neurovascular commercial presence supports its distribution of the Neuroform platform across major global markets.

Technology and Practice Trends

• Self-expanding stent adoption: Self-expanding designs are now standard across neurovascular stent platforms, allowing conformity to vessel anatomy without balloon deployment trauma and enabling treatment of complex aneurysm morphologies including fusiform and dissecting presentations.
• Flow diversion expansion: Flow diversion stents continue to expand their clinical indications beyond initial large aneurysm approvals, with growing physician experience and accumulating outcome data supporting broader adoption across aneurysm types.
• Intrasaccular device growth: Intrasaccular stents are the fastest-growing segment, offering physicians a less invasive deployment pathway and gaining adoption in aneurysm morphologies and patient profiles where traditional stent-assisted coiling or flow diversion carries greater procedural complexity.
• MRI-compatible and biocompatible materials: Improvements in stent material science are reducing thrombogenicity, improving post-implant imaging compatibility, and expanding the range of patients for whom stent-based treatment is practical and safe.
• Miniaturization for distal access: Ongoing reductions in stent delivery profile and diameter are enabling placement in smaller arteries and more distal locations, broadening the anatomical scope of treatable aneurysms.
• Imaging-driven diagnosis growth: Improvements in CT angiography and MRI are increasing the detection rate of unruptured aneurysms, expanding the eligible patient population and supporting procedure volume growth across all three stent categories.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• Where are the largest and fastest-growing opportunities across traditional neurovascular stents, flow diversion stents, and intrasaccular stents through 2032?
• How are self-expanding designs, biocompatible coatings, and MRI-compatible materials expanding the range of aneurysms that can be treated endovascularly with stent-based approaches?
• What is the growth outlook for flow diversion stents as the largest market segment, and how are expanding clinical indications and accumulating outcome data shaping physician adoption?
• Why are intrasaccular devices the fastest-growing segment, and which aneurysm morphologies and patient profiles are driving this adoption?
• What is the lasting commercial and clinical impact of the SAMMPRIS trial and flow diversion safety concerns on stent use across indications and patient populations?
• Which companies lead each stent category and how are the LVIS, Pipeline Flex, and Neuroform EZ platforms differentiated by design, indication, and market positioning?
• How is improved imaging technology expanding the diagnosed aneurysm population and translating into incremental unit demand across all three stent device types?
• What are the key risks to market growth, including physician resistance, clinical evidence uncertainty, reimbursement variability, and competitive pressure from non-stent endovascular alternatives?

The Global Neurovascular Stent Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail across all three device categories. Use it to quantify demand, benchmark competitors, and plan commercial strategy across a steadily growing market shaped by technology advancement, evolving clinical evidence, and a shifting mix toward newer and faster-growing stent modalities.

TABLE OF CONTENT

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Neurovascular Stent Market

• 9.1 Executive Summary
  • 9.1.1 Global Neurovascular Stent Market Overview
  • 9.1.2 Competitive Analysis
  • 9.1.3 Procedures Included
  • 9.1.4 Markets Included
  • 9.1.5 Regions Included
• 9.2 Introduction
• 9.3 Procedure Numbers
  • 9.3.1 Total Neurovascular Stent Procedures
  • 9.3.2 Traditional Stent Procedures
  • 9.3.3 Flow Diversion Stent Procedures
  • 9.3.4 Intrasaccular Stent Procedures
• 9.4 Market Overview
  • 9.4.1 By Segment
  • 9.4.2 By Region
• 9.5 Market Analysis And Forecast
  • 9.5.1 Total Neurovascular Stent Market
  • 9.5.2 Traditional Neurovascular Stent Market
  • 9.5.3 Flow Diversion Stent Market
  • 9.5.4 Intrasaccular Stent Market
• 9.6 Drivers And Limiters
  • 9.6.1 Market Drivers
  • 9.6.2 Market Limiters
• 9.7 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

• Chart 9-1: Neurovascular Stent Market, Global, 2025 & 2032
• Chart 9-2: Neurovascular Stent Procedures, Global, 2025
• Chart 9-3: Neurovascular Stent Procedures by Segment, Global, 2022 - 2032
• Chart 9-4: Neurovascular Stent Market by Segment, Global, 2022 - 2032
• Chart 9-5: Neurovascular Stent Market by Region, Global, 2022 - 2032
• Chart 9-6: Leading Competitors, Neurovascular Stent Market, Global, 2025

LIST OF FIGURES

• Figure 9-1: Neurovascular Stent Markets Covered
• Figure 9-2: Neurovascular Stent Markets Covered
• Figure 9-3: Neurovascular Stent Regions Covered, Global (1 of 2)
• Figure 9-4: Neurovascular Stent Regions Covered, Global (2 of 2)
• Figure 9-5: Neurovascular Stent Procedures by Segment, Global, 2022 - 2032
• Figure 9-6: Neurovascular Stent Procedures by Region, Global, 2022 - 2032
• Figure 9-7: Neurovascular Stent Procedures by Country, North America, 2022 - 2032
• Figure 9-8: Neurovascular Stent Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 9-9: Neurovascular Stent Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 9-10: Neurovascular Stent Procedures by Country, Western Europe, 2022 - 2032
• Figure 9-11: Neurovascular Stent Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 9-12: Neurovascular Stent Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 9-13: Neurovascular Stent Procedures by Country, Middle East, 2022 - 2032
• Figure 9-14: Neurovascular Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 9-15: Neurovascular Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 9-16: Neurovascular Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 9-17: Neurovascular Stent Procedures by Country, Africa, 2022 - 2032
• Figure 9-18: Traditional Stent Procedures by Region, Global, 2022 - 2032
• Figure 9-19: Traditional Stent Procedures by Country, North America, 2022 - 2032
• Figure 9-20: Traditional Stent Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 9-21: Traditional Stent Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 9-22: Traditional Stent Procedures by Country, Western Europe, 2022 - 2032
• Figure 9-23: Traditional Stent Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 9-24: Traditional Stent Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 9-25: Traditional Stent Procedures by Country, Middle East, 2022 - 2032
• Figure 9-26: Traditional Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 9-27: Traditional Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 9-28: Traditional Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 9-29: Traditional Stent Procedures by Country, Africa, 2022 - 2032
• Figure 9-30: Flow Diversion Stent Procedures by Region, Global, 2022 - 2032
• Figure 9-31: Flow Diversion Stent Procedures by Country, North America, 2022 - 2032
• Figure 9-32: Flow Diversion Stent Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 9-33: Flow Diversion Stent Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 9-34: Flow Diversion Stent Procedures by Country, Western Europe, 2022 - 2032
• Figure 9-35: Flow Diversion Stent Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 9-36: Flow Diversion Stent Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 9-37: Flow Diversion Stent Procedures by Country, Middle East, 2022 - 2032
• Figure 9-38: Flow Diversion Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 9-39: Flow Diversion Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 9-40: Flow Diversion Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 9-41: Flow Diversion Stent Procedures by Country, Africa, 2022 - 2032
• Figure 9-42: Intrasaccular Stent Procedures by Region, Global, 2022 - 2032
• Figure 9-43: Intrasaccular Stent Procedures by Country, North America, 2022 - 2032
• Figure 9-44: Intrasaccular Stent Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 9-45: Intrasaccular Stent Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 9-46: Intrasaccular Stent Procedures by Country, Western Europe, 2022 - 2032
• Figure 9-47: Intrasaccular Stent Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 9-48: Intrasaccular Stent Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 9-49: Intrasaccular Stent Procedures by Country, Middle East, 2022 - 2032
• Figure 9-50: Intrasaccular Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 9-51: Intrasaccular Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 9-52: Intrasaccular Stent Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 9-53: Intrasaccular Stent Procedures by Country, Africa, 2022 - 2032
• Figure 9-54: Neurovascular Stent Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 9-55: Neurovascular Stent Market by Region, Global, 2022 - 2032 (US$M)
• Figure 9-56: Neurovascular Stent Market, Global, 2022 - 2032
• Figure 9-57: Units Sold by Region, Neurovascular Stent Market, Global, 2022 - 2032
• Figure 9-58: Average Selling Price by Region, Neurovascular Stent Market, Global, 2022 - 2032 (US$)
• Figure 9-59: Market Value by Region, Neurovascular Stent Market, Global, 2022 - 2032 (US$M)
• Figure 9-60: Traditional Neurovascular Stent Market, Global, 2022 - 2032
• Figure 9-61: Units Sold by Region, Traditional Neurovascular Stent Market, Global, 2022 - 2032
• Figure 9-62: Average Selling Price by Region, Traditional Neurovascular Stent Market, Global, 2022 - 2032 (US$)
• Figure 9-63: Market Value by Region, Traditional Neurovascular Stent Market, Global, 2022 - 2032 (US$M)
• Figure 9-64: Flow Diversion Stent Market, Global, 2022 - 2032
• Figure 9-65: Units Sold by Region, Flow Diversion Stent Market, Global, 2022 - 2032
• Figure 9-66: Average Selling Price by Region, Flow Diversion Stent Market, Global, 2022 - 2032 (US$)
• Figure 9-67: Market Value by Region, Flow Diversion Stent Market, Global, 2022 - 2032 (US$M)
• Figure 9-68: Intrasaccular Stent Market, Global, 2022 - 2032
• Figure 9-69: Units Sold by Region, Intrasaccular Stent Market, Global, 2022 - 2032
• Figure 9-70: Average Selling Price by Region, Intrasaccular Stent Market, Global, 2022 - 2032 (US$)
• Figure 9-71: Market Value by Region, Intrasaccular Stent Market, Global, 2022 - 2032 (US$M)
• Figure 9-72: Leading Competitors, Neurovascular Stent Market, Global, 2025